Skip to main content
Caplight Logo









Aerska

Aerska

Private
DublinHealthcare & Life Scienceshttps://www.aerska.com/

Last Round

Series A

May 20, 2026

Total Funding Raised

$119M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Aerska is a biotechnology company developing RNA interference (RNAi) medicines designed to treat, delay, and prevent diseases of the brain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

RNA interferenceRNAi therapyblood-brain barrier deliveryAntibody-Oligonucleotide ConjugateAOC platformgene silencingbrain shuttleCNS drug deliveryneurological disease therapyoligonucleotide therapeuticsgenetic medicinedrug delivery platformAlzheimer's diseaseParkinson's diseasebiopharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aerska Comparables

Compare Aerska with similar companies based on industry and business-model similarity.

Aerska comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cenos Therapeutics
87%
CereCura Nanotherapeutics
80%
Qinotto, Inc.
79%

Aerska Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 20, 2026
Series AFeb 9, 2026
SeedOct 2, 2025

Aerska Investors

Notable investors and investment history

Aerska investors
InvestorRounds
Iaso VenturesSeries A
Backed VCSeed
Saras CapitalSeed
LingottoSeed
BlueYard CapitalSeed
Ada VenturesSeed
age1Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 18, 2026

    Grew 27% QoQ, from 22 to 28 employees.

  • Jun 25, 2026

    Grew 35% QoQ, from 20 to 27 employees.

Aerska Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aerska Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aerska's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin
Employee Range28
Year Founded2025
Last FundingMay 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?